Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZVHSB)

• Drug Name: 2-(N-Morpholino)-Ethanesulfonic Acid Drug Info
• Synonyms: Jsp003925

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 4478249
  ChEBI ID: CHEBI:39408
  CAS Number: CAS 4432-31-9
  TTD Drug ID: DMZVHSB

Molecule-Related Drug Atlas

Drug(s) Targeting Chymase (CYM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SUN13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[2]
JNJ-10311795	DM7OTQS	Chronic obstructive pulmonary disease	CA22	Phase 2	[3]
ASB17061	DMNVU28	Atopic dermatitis	EA80	Phase 2	[4]
BAY 11-42524	DM8SNEM	Left ventricular dysfunction	BD11	Phase 2	[5]
BAY 1142524	DMHKTGX	Myocardial infarction	BA41-BA43	Phase 2	[6]
Benzylsulfinic Acid	DM7XK28	Discovery agent	N.A.	Investigative	[7]
KM-01221	DMG594K	Cardiovascular disease	BA00-BE2Z	Investigative	[8]
Y-40613	DM412IV	Discovery agent	N.A.	Investigative	[9]
Rac-2q	DMD5TPH	Discovery agent	N.A.	Investigative	[10]
Phenylalanylmethane	DMZNFT2	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Bacterial Glucosamine-6-phosphate synthase (Bact glmS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucose-6-Phosphate	DMKY1L4	N. A.	N. A.	Phase 1	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-6-Phosphate	DMR0EVN	Discovery agent	N.A.	Investigative	[1]
Glutamine Hydroxamate	DMT7K0U	Discovery agent	N.A.	Investigative	[1]
2-Deoxy-2-Amino Glucitol-6-Phosphate	DMBMK4T	Discovery agent	N.A.	Investigative	[1]
Glucosamine 6-Phosphate	DMY590Q	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Bacterial Flavohemoglobin (Bact hmp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[11]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[12]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[13]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[14]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[15]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[16]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[17]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[18]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[19]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[20]

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazobactam	DM3XNUI	Appendicitis	DB10	Approved	[21]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[22]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[23]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[24]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[25]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[26]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[27]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[28]
ME-1071	DMEMQ5J	Bacterial infection	1A00-1C4Z	Phase 1	[29]
OP-0595	DMECVP9	Bacterial infection	1A00-1C4Z	Phase 1	[30]

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[31]
BVT.2733	DM6RUKX	Lupus	4A40	Phase 3	[32]
INCB13739	DMLQ3PO	Type-2 diabetes	5A11	Phase 2a	[33]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[34]
JTT-654	DM50M2R	Type-2 diabetes	5A11	Phase 2	[35]
RG-4929	DMT4QRD	Metabolic disorder	5C50-5D2Z	Phase 2	[35]
BMS-770767	DMTVGY7	Hypercholesterolaemia	5C80.0	Phase 2	[35]
UE-2343	DMIERPK	Alzheimer disease	8A20	Phase 2	[36]
AZD-4017	DML9M5S	Ocular hypertension	9C61.01	Phase 2	[35]
Xanamem	DM580GT	Alzheimer disease	8A20	Phase 1/2	[37]

Drug(s) Targeting Polypeptide deformylase (PDF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[38]
Meprobamate	DMHM93Y	Anxiety		Approved	[39]
Pralatrexate	DMAO80I	Breast cancer	2C60-2C65	Approved	[40]
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[41]
Trimetrexate	DMDEA85	Toxoplasmosis	1F57	Approved	[42]
MCB-3837	DM0R4Z5	Malaria	1F40-1F45	Approved	[39]
Chlorproguanil	DM1IFGT	Malaria	1F40-1F45	Approved	[39]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[43]
Metoprine	DM5GQD7	Advanced cancer	2A00-2F9Z	Phase 2	[44]
Aminopterin	DMQ9RBV	leukaemia	2A60-2B33	Withdrawn from market	[45]

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[46]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[47]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[48]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[49]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[50]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[51]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[52]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[53]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[53]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[53]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[1]
Bacterial Flavohemoglobin (Bact hmp)	TTNAW8S	HMP_ECOLI	Inhibitor	[1]
Bacterial Glucosamine-6-phosphate synthase (Bact glmS)	TTC67I0	GLMS_ECOLI	Inhibitor	[1]
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]
Chymase (CYM)	TT8VUE0	CMA1_HUMAN	Inhibitor	[1]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[1]
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[1]
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
• [3] Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
• [4] Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
• [5] ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
• [6] Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
• [7] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340).
• [9] Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7.
• [10] Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.
• [11] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [13] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [14] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [15] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [16] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [18] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [19] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [20] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [21] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [22] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [23] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [24] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [25] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [26] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [27] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [28] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [29] Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
• [30] OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
• [31] Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
• [32] Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
• [33] Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
• [34] 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
• [35] New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.
• [38] Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
• [39] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [40] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [41] Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
• [42] Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
• [43] Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
• [44] Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
• [45] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [46] Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
• [47] Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
• [48] Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
• [49] Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
• [50] Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
• [51] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
• [52] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [53] A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.